404. Research laboratory

Head: Szilvia Bősze, Ph.D.

Address: Budapest, Pázmány P. sétány 1/A, 404.
Telefon: 06-1-372-2500
Fax: 06-1-372-2620


Szilvia Bősze, PhD; Research Associate Professor
Kata Horváti, PhD, Research Assistant Professor
Zsuzsa Baranyai, Research Assistant
Gergely Kohut, PhD student
Lilla Horváth, PhD student

M.Sc. students:

Anna Lőrincz

B.Sc. students:

Aysa Dormaeva
Dóra Illik
Zsófia Szabó
Gergely Réti

Despite five decades of control and research programs tuberculosis (TB) remains the first cause of mortality due to a single pathogen. A third of the world population is believed to be latently infected with TB. Latent TB (LTBI) is an asymptomatic phase of the disease during which the bacilli persist within their hosts. The risk of developing active TB can be higher among newborns, seniors, HIV-positive patients, people with diabetes, cancer patients, organ transplant recipients, people undergoing treatment for autoimmune diseases. Therefore there is an urgent need to develop new diagnostics and agents active against TB.

The long-term aim of our research project is to improve the immunodiagnosis of LTBI, using peptide-based synthetic antigens. A detailed study of the promising synthetic antigens would be advantageous in order to make progress towards differentiating not only between TB infection and BCG vaccination, but also between LTBI and the early stage of active TB. The futher aim of our research is the preparation and evaluation of new potential antimycobacterial agents. Considering that mycobacteria can survive in host cell its elimination could be more efficient with host cell directed delivery of chemoterapetic agents. To enhance the cellular uptake and the host cell specificity of the new and recently used chemotherapeutic agents different approaches will be developed. Due to the optimised and selective cellular uptake more effective therapy can be achieved.

Recent publications:

1.Ábrahám Á, Baranyai Zs, Gyulai G, Pári E, Horváti K, Bősze Sz, Kiss É (2016)
Comparative analysis of new peptide conjugates of antitubercular drug candidates-model membrane and in vitro studies.
Colloids Surf B Biointerfaces. 28; 147: 106-115. [IF: 3.902]

2. Horváti K, Bősze Sz, Gideon HP, Bacsa B, Szabó TG, Goliath R, Rangaka MX, Hudecz F, Wilkinson RJ, Wilkinson KA (2016)
Population tailored modification of tuberculosis specific interferon-gamma release assay,
J Infection 72:179-188. [IF: 4.441] (citations: 1)

3. Bősze Sz, Hudecz F (2016)
Proteins and peptides for the immunodiagnosis and therapy of Mycobacterium tuberculosis infections
Amino Acids, Peptides and Proteins, 40, pp. 146-198.
DOI: 10.1039/9781782622680-00146

4. Baranyai Z, Krátký M, Vinšová J, Szabó N, Senoner Z, Horváti K, Stolaříková J, Dávid S, Bősze Sz (2015)
Combating highly resistant emerging pathogen Mycobacterium abscessus and Mycobacterium tuberculosis with novel salicylanilide esters and carbamates.
Eur J Med Chem. 101:692-704. [IF: 3.447]

5. Krátký M, Bősze Sz, Baranyai Z, Szabó I, Stolaříková J, Paraskevopoulos G, Vinšová (2015) J. Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates
Bioorg Med Chem. 23(4):868-75. [IF: 2.951]

6. Horváti K, Bacsa B, Szabó N, Fodor K, Balka G, Rusvai M, Kiss É, Mező G, Grolmusz V, Vértessy B, Hudecz F, Bősze Sz (2015)
Antimycobacterial activity of peptide conjugate of pyridopyrimidine derivative against Mycobacterium tuberculosis in a series of in vitro and in vivo models.
Tuberculosis (Edinb). 95:S207-211 [IF: 3.503]

7. Horváti K, Bacsa B, Kiss E, Gyulai G, Fodor K, Balka G, Rusvai M, Szabó E, Hudecz F, Bősze Sz (2014)
Nanoparticle encapsulated lipopeptide conjugate of antitubercular drug isoniazid: in vitro intracellular activity and in vivo efficacy in a Guinea pig model of tuberculosis.
Bioconjug Chem. 25(12):2260-2268. [IF: 4.821]

8. Kiss É, Gyulai G, Pénzes CB, Idei M, Horváti K, Bacsa B, Bősze Sz (2014)
Tunable surface modification of PLGA nanoparticles carrying new antitubercular drug candidate.
Colloid Surface A. 458: 178-186. [IF: 2.354]